- Zealand's management will provide an update on the status and prospects for the business, on strategy and on recent portfolio developments
- Focus on two key proprietary pipeline products; ZP1848 for Short Bowel Syndrome and ZP4207 for hypoglycemia
- Both events will include keynote presentations from medical and industry experts
COPENHAGEN, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Zealand informs that it will host Capital Markets Days for investors and analysts in New York City on Tuesday 3 November 2015 and at the company's offices in Copenhagen (Glostrup) on Wednesday 18 November 2015.
Both events will include an update on the status and prospects of Zealand's business and on the strategy, presented by Britt Meelby Jensen, President and CEO. Dr. Adam Steensberg, Senior Vice President for Development and Chief Medical Officer will present recent advances and status of two key proprietary products in the company's growing pipeline of novel peptide therapeutics: ZP1848 for the treatment of Short Bowel Syndrome and ZP4207 for more effective and convenient treatment and control of hypoglycemia.
In addition, presentations by two medical and industry experts will provide important insights on Short Bowel Syndrome and hypoglycemia in diabetes.
No material new information will be disclosed at the events and detailed program will be announced in due course.
Capital Markets Day in New York City ? Event details
|Date:||Tuesday, 3 November 2015|
|Time:||1:30 - 4:30 pm ET (lunch will be served from 1:00 pm)|
|Venue:||Dechert Law Firm offices, 1095 Avenue of the Americas, at the corner of 42th West facing Bryant Park, New York City|
|Webcast:||This event will not be webcast|
|Registration:|| Before end of business ET on Friday, 30 October 2015 |
to Danielle Spangler, email@example.com
Capital Markets Day in Glostrup, Copenhagen ? Event details
|Date:||Wednesday, 18 November 2015|
|Time:||1:30 - 4:30 pm CET (lunch will be served from 1:00pm CET)|
|Venue:||Zealand offices, Smedeland 36, 2600 Glostrup, Copenhagen|
|Webcast:||Presentations on the day will be transmitted via live webcast and a recording will be available after the event|
|Registration:|| Before end of business CET on Monday 16 November |
to Annette Borring Kjaer, firstname.lastname@example.org
For further information, please contact:
Hanne Leth Hillman, Senior Vice President, Head of Investor Relations and Communications
Tel: +45 50 60 36 89, email: email@example.com
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a medicinal biotech company with leading expertise in the identification, design and development of novel peptide medicines. Zealand has a proprietary pipeline of novel drug candidates and a portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim - primarily in the fields of cardio-metabolic diseases and acute care indications.
The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development, ZP1848 for Short Bowel Syndrome in Phase II development and the stable glucagon analogue, ZP4207 as a single-dose rescue pen for severe hypoglycemia in preparation for Phase II, and ZP4207 as multiple-dose use for the correction of mild to moderate hypoglycemia in evaluation for the next clinical development step after Phase I, as well as several preclinical peptide therapeutics.
Zealand has invented lixisenatide, a once-daily prandial GLP-1 agonist, which is marketed globally (ex-US) by Sanofi for the treatment of Type 2 diabetes and since end September 2015 has been under review by the FDA in the US. The license agreement with Sanofi also covers a single-product combination of lixisenatide and insulin glargine (Lantus(r)) which is on track for regulatory submission in the US in Q4 2015 and in Europe in Q1 2016.
The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.comor follow us on Twitter @ZealandPharma
Source: Zealand Pharma A/S